NEW YORK (360Dx) – ProAxsis said this week it has achieved CE marking for its ProteaseTag Active Proteinase 3 immunoassay.

Proteinase 3 is a neutrophilic protease, which has been associated with the inflammation and destruction of the lung matrix in respiratory diseases including chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis. ProAxsis and an unnamed US-based biotechnology company codeveloped the assay as part of an ongoing collaboration.

ProAxsis also has made its first commercial sale of the ProteaseTag Active Proteinase 3 immunoassay, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.